Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy-V45I6 Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy-V45I6 Download 0753 Predictors of Residual sleep apnea in OSA patients on PAP-V45IS1 Combined intermittent and sustained hypoxia is a novel and deleterious cardio-metabolic phenotype-V45I6
